11/15
08:03 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.
11/15
02:22 am
ocul
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... [Yahoo! Finance]
Medium
Report
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... [Yahoo! Finance]
11/14
07:09 am
ocul
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights [Yahoo! Finance]
High
Report
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights [Yahoo! Finance]
11/14
07:00 am
ocul
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
High
Report
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
11/13
07:30 am
ocul
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
Medium
Report
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
11/12
07:30 am
ocul
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
Low
Report
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
11/6
07:30 am
ocul
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Low
Report
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
10/16
08:44 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Medium
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/16
08:31 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Medium
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
10/15
09:29 am
ocul
Ocular Therapeutix announces accelerated timelines for trial of AXPAXLI in wet AMD [Seeking Alpha]
Low
Report
Ocular Therapeutix announces accelerated timelines for trial of AXPAXLI in wet AMD [Seeking Alpha]
10/15
07:30 am
ocul
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
Medium
Report
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
10/14
11:28 am
ocul
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? [Yahoo! Finance]
Medium
Report
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? [Yahoo! Finance]
10/11
05:53 am
ocul
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors [Seeking Alpha]
Medium
Report
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors [Seeking Alpha]
10/9
04:05 pm
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/9
07:30 am
ocul
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
Low
Report
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
10/8
10:38 am
ocul
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength [Yahoo! Finance]
Low
Report
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength [Yahoo! Finance]
9/25
07:30 am
ocul
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
Medium
Report
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
9/12
04:05 pm
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/5
07:30 am
ocul
Ocular Therapeutix™ to Present at September Retina Meetings
Low
Report
Ocular Therapeutix™ to Present at September Retina Meetings
9/4
07:44 am
ocul
Ocular Therapeutix™ to Present at Two Investor Conferences in September [Yahoo! Finance]
Low
Report
Ocular Therapeutix™ to Present at Two Investor Conferences in September [Yahoo! Finance]
9/4
07:30 am
ocul
Ocular Therapeutix™ to Present at Two Investor Conferences in September
Low
Report
Ocular Therapeutix™ to Present at Two Investor Conferences in September
9/3
03:19 am
ocul
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer [Yahoo! Finance]
Medium
Report
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer [Yahoo! Finance]